Aurinia Pharmaceuticals Inc.
AUPH
$7.77
-$0.15-1.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 4.34% | -11.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.34% | -11.66% | |||
| Cost of Revenue | 4.82% | 50.40% | |||
| Gross Profit | 4.20% | -21.27% | |||
| SG&A Expenses | -45.08% | -12.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 217.72% | -69.52% | |||
| Total Operating Expenses | -24.96% | -7.03% | |||
| Operating Income | 200.44% | -33.76% | |||
| Income Before Tax | 1,975.79% | -92.08% | |||
| Income Tax Expenses | 492.58% | -156.02% | |||
| Earnings from Continuing Operations | 1,533.59% | -90.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,533.59% | -90.04% | |||
| EBIT | 200.44% | -33.76% | |||
| EBITDA | 123.32% | -24.02% | |||
| EPS Basic | 1,563.37% | -89.93% | |||
| Normalized Basic EPS | 60.33% | 12.21% | |||
| EPS Diluted | 1,484.16% | -89.90% | |||
| Normalized Diluted EPS | 61.66% | 10.08% | |||
| Average Basic Shares Outstanding | -2.29% | -0.61% | |||
| Average Diluted Shares Outstanding | -3.03% | 1.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||